Exclusive License to NIH Invention Used in Lilly Antibody Treatment Contains Termination Clause and Government-Use Rights

KEI has reviewed an exclusive license between the National Institute of Allergy and Infectious Diseases (NIAID) and AbCellera Biologics (“AbCellera”) concerning a technology invented by NIAID that apparently is being used for the Eli Lilly (“Lilly”) antibody treatment for COVID-19… Continue Reading

Novavax and Inovio COVID-19 Vaccine Contracts Limit Prices Companies Can Charge for Their Products

One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading

President Ursula von der Leyen on COVID-19 (Davos Agenda Week): “And now, the companies must deliver. They must honour their obligations.”

On Tuesday, 26 January 2021, Dr. Ursula von der Leyen, President of the European Commission delivered a special address at “Davos Agenda Week” devoting much of her speech to the European Union’s response to the COVID-19 pandemic. While President von… Continue Reading

WHO EB 148: KEI’s statement on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies

At the meeting of the World Health Organization’s 148th Executive Board, Knowledge Ecology International delivered the following remarks on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies on Friday, 22 January… Continue Reading

EB 148: WHO’s COVID-19 Technology Access Pool (C-TAP) comes under scrutiny

On Tuesday, 19 January 2021, the World Health Organization’s (WHO) Executive Board discussed the COVID-19 response. In these discussions, Knowledge Ecology International (KEI), and Health Action International (HAI) expressed concerns over WHO’s leadership of the COVID-19 Technology Access Pool (C-TAP).… Continue Reading

KEI Comments to NIH on Exclusive and Co-Exclusive Licenses to Senti Bio

Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on January 12, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like… Continue Reading